The HIV cure field desperately needs one or more biomarkers that can allow us to determine 1) whether viral rebound is likely if antiretroviral therapy (ART) is to be stopped, 2) the likely duration of the lag phase or “remission” period prior to viral rebound, and 3) the likelihood of incipient viral rebound during ART interruption (signaling the need to immediately re-initiate ART). The only rigorous method available to achieve this goal involves experimental cessation of ART in analytical treatment interruption (ATI) studies, allowing for exploration of host and viral features that predict viral rebound kinetics. Our lab is engaged in a dynamic interdisciplinary collaboration to discover biomarkers of HIV persistence and predictors of viral rebound when ART is stopped: